SpinaFX Medical’s Triojection earned the FDA’s breakthrough device designation, according to an Aug. 15 news release.
Triojection is a minimally invasive, image-guided procedure to reduce pressure within the disc and alleviate nerve compression for lumbar disc herniation patients.
With breakthrough designation, the flagship device will have prioritized access to the FDA for regulatory processes.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
